Acambis is a leading developer of vaccines to prevent and treat infectious diseases. Recognized internationally as the leading producer of smallpox vaccines, Acambis is developing an investigational smallpox vaccine, ACAM2000, and is manufacturing emergency-use stockpiles of this investigational vaccine for the US Government and other governments around the world. In January 2006, Acambis submitted the first portion of a Biologics License Application with the FDA to seek licensure for the vaccine and expects a decision by the FDA by the end of the year. Acambis is also developing an attenuated smallpox vaccine, MVA3000, under contracts with the US National Institutes of Health.
Acambis’ Miami-based subsidiary Berna Products Corporation markets Vivotif®, the world's only licensed oral typhoid vaccine, in North America. The company’s investigational vaccine against Japanese encephalitis, ChimeriVax-JE, is undergoing Phase 3 clinical testing. Acambis also has the most advanced investigational vaccine against the West Nile virus, which has spread to 48 states in the last six years, and a vaccine against Clostridium difficile bacteria, a leading cause of hospital-acquired infections.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, with operations in Canton, Massachusetts; Rockville, Maryland; and Miami, Florida. We invite you to learn more about Acambis and our employment opportunities at www.acambis.com.
Last Updated: 02-15-2006